Cyprotex to sell drug transporter assays

CYPROTEX has announced a deal to sell a range of drug transporter services developed by Hungarian firm Solvo Biotechniology to its customers.

Cyprotex, which runs a range of pre-clinical testing services for drug discovery companies, said that adding Solvo’s range to its own offer would broaden the tests it can carry out for clients.

Drug transporters are a family of proteins that actively move substances across cellular membranes, both into and out of the cells. In the past few years, they have been recognised as playing an important role in pharmacokinetics, and have been identified as responsible for toxicities and drug-drug interactions that were not previously understood.   

Solvo Biotechnology has specialized in drug transporters since 1999 and offers the world’s largest range of drug-transporter assays.  

Dr. Katya Tsaioun, Cyprotex’s Chief Scientific Officer, said: “The role of drug transporters in causing toxicities and drug-drug interactions has only recently become understood.  The US FDA has moved quickly in recommending in vitro testing for drug-transporter activity at the preclinical stage.   

“As Cyprotex is committed to serving all of our clients’ preclinical ADME-Tox needs, and as Solvo Biotechnology has over a decade of focus on transporters and deep expertise in this field, Cyprotex is delighted to partner with Solvo Biotechnology for providing these services which pharmaceutical companies need for de-risking their drug candidates before human clinical trials.”